Navigation Links
DFB Pharmaceuticals Appoints Maxwell Lea to Vice President Business Development and Corporate Finance
Date:4/23/2009

FORT WORTH, Texas, April 23 /PRNewswire/ -- DFB Pharmaceuticals, Inc., has announced the promotion of Maxwell A. Lea, III, to Vice President Business Development and Corporate Finance. Mr. Lea was most recently Director of Corporate Development and Finance for the company.

"Since joining DFB in 2002, Maxwell has positively impacted every level of our company and its affiliate businesses," said Michael A. Patterson, Chief Financial Officer of DFB Pharmaceuticals. "I can say without reservation that our companies have excelled due to his successes."

As Vice President, Mr. Lea will manage DFB's capital raising and financing activities, business development initiatives and strategic planning. He will also be responsible for business development efforts for Healthpoint, Ltd., a DFB affiliate company also based in Fort Worth.

His role for Healthpoint, a branded specialty pharmaceutical company, will be to serve as a member of its senior staff group, managing a team that focuses on further expanding the Healthpoint product portfolio through the acquisition of products and technologies.

Additionally, Mr. Lea has also assumed responsibility for Healthpoint International, with employees in Canada, Puerto Rico and Switzerland and distributors in numerous countries around the globe.

Prior to his career at DFB, Mr. Lea was an investment banker with Banc of America Securities. He received a Bachelor of Arts in Economics from Vanderbilt University and a Master of Business Administration from The Fuqua School of Business at Duke University, where he graduated as a Fuqua Scholar. He has earned the Chartered Financial Analyst (CFA) designation.

DFB Pharmaceuticals, Inc. is a privately held Texas corporation that provides technology-driven pharmaceutical products, outsourcing services, and licensing opportunities through its affiliate partners to
'/>"/>

SOURCE DFB Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... N.C. , May 29, 2015 ... affairs function into roles involving clinical development, regulatory ... its responsibilities have grown, Medical Affairs has faced ... as a global group. And while its importance ... it challenging to identify strong performance metrics to ...
(Date:5/29/2015)... , May 29, 2015 In recent ... the availability of Big Data that can generate valuable ... come with utilizing Big Data have caused the biopharmaceutical ... other industries. According to a recent ... participants already have a Big Data team or function ...
(Date:5/29/2015)... , May 29, 2015 ... company, today announces that an abstract on the latest ... inhibitor of the Axl receptor tyrosine kinase, and BGB10C9, ... BerGenBio, has been published in conjunction with the 2015 ... Chicago , May 29 - June ...
(Date:5/29/2015)... 2015 GeneWEAVE, Inc ., ... announced that initial feasibility data supporting the use ... susceptibility testing from positive blood cultures will be ... 2015 in New Orleans, LA. The Company’s Smarticles™ ... that can quickly detect bacteria and assess antibiotic ...
Breaking Biology Technology:Creating an Effective Pharmaceutical Medical Affairs Group with Global Capabilities 2New Study Details Current & Future Big Data Trends Across Medical Affairs Functions 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 2BGB324 and BGB10C9 Show Promise in Models of Pancreatic Cancer 3Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3
... Corp.,(TSX, FSE: "HBP") today announced financial results for the first quarter,of ... - Subsequent to the first quarter, the Company ... of common shares, subject to closing, ... Segal remaining the Company,s Chief Executive ...
... two important surgical tools: Baxter,s ... human thrombin and Pfizer,s GELFOAM, ... announced the Food and Drug Administration approval of,GELFOAM(R) Plus ... Plus is the only available hemostasis kit that contains,Pfizer,s ...
... Lilly to Acquire Exclusive Rights to Novel Late-Stage Molecule for ... ... 17 ,Eli Lilly and Company (NYSE: LLY ) and ... have entered into a licensing and,development agreement granting Lilly exclusive ...
Cached Biology Technology:Helix BioPharma announces Q1 2008 financial results 2Helix BioPharma announces Q1 2008 financial results 3Helix BioPharma announces Q1 2008 financial results 4Helix BioPharma announces Q1 2008 financial results 5Helix BioPharma announces Q1 2008 financial results 6Helix BioPharma announces Q1 2008 financial results 7Helix BioPharma announces Q1 2008 financial results 8Helix BioPharma announces Q1 2008 financial results 9Helix BioPharma announces Q1 2008 financial results 10Helix BioPharma announces Q1 2008 financial results 11Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 2Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 3Baxter Announces FDA Approval of GELFOAM(R) Plus Hemostasis Kit 4Lilly and BioMS Medical Announce Global Licensing and Development Agreement 2Lilly and BioMS Medical Announce Global Licensing and Development Agreement 3Lilly and BioMS Medical Announce Global Licensing and Development Agreement 4Lilly and BioMS Medical Announce Global Licensing and Development Agreement 5Lilly and BioMS Medical Announce Global Licensing and Development Agreement 6
(Date:5/29/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/2w6zgs/facial ) has ... Market by Solution, by Software, by Hardware, by ... report to their offering. The last ... more efficient and cost effective. This has helped ... the commercial sector. The development of 3D facial ...
(Date:5/28/2015)... 2015 Industry analyst firm n-tech Research ... titled "Markets for Self-Healing Materials: 2015-2022." According to the ... vascular systems, biomaterials, relevant shape memory materials and ... billion by 2020. The report is ... smart materials. Other recent n-tech reports have included studies ...
(Date:5/27/2015)...   Codonics (codonics.com), a global ... documentation solutions and Omnicell  (omnicell.com), a ... is pleased to announce their state of ... System® (SLS), an award-winning FDA class 2 ... Anesthesia Workstation, helps prevent medication errors, streamlines ...
Breaking Biology News(10 mins):Global advanced Facial Recognition Market Expected to Grow From $2.77 Billion in 2015 to $6.19 Billion in 2020, at an Estimated CAGR of 17.4% 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 2The Market for Self-Healing Materials to Reach $2.7 Billion by 2020 Says New n-tech Research Study 3Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4
... described fossil whales---a pregnant female and a male of the ... insights into how whales made the transition from land to ... 2000 and 2004 and studied at the University of Michigan, ... online journal PLoS . U-M paleontologist Philip Gingerich, ...
... In 2005, a woman who had trouble sleeping asked ... sleep disorders specialist at the Mayo Clinic campus in ... interrupts sleep because of unpleasant sensations in the legs ... relieved by movement. Restless legs syndrome affects ...
... State University already have shown that gardening can offer enough ... In research to be published in February in the journal ... health benefits of gardening is keeping older hands strong and ... older adults who are gardeners have better hand strength and ...
Cached Biology News:Early whales gave birth on land, fossil find reveals 2Mayo Clinic researchers suspect a novel gene is causing restless legs syndrome in a large family 2Gardening gives older adults benefits like hand strength and self-esteem 2